(Source: Resverlogix Corporation) In addition, preliminary results from an Australian sponsored trial have yet to verify whether the mechanism of RVX-208 action may affect glucose metabolism. TSX Exchange Symbol: RVX CALGARY, July 23, 2014/CNW/ - Resverlogix Corp. (TSX: RVX) announced today findings from the recent analysis of Major Adverse Cardiovascular Events (MACE) data in patients with diabetes mellitus (DM) enrolled in both the ASSURE and SUSTAIN trials. In ASSURE, MACE was a pre-specified endpoint and it was confirmed to be statistically and significantly reduced in patients with DM treated with RVX-208 vs. placebo. The latest finding reinforces the potential benefit of RVX-208,...
↧